title: The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies.
abstract: Teriflunomide is a once-daily oral immunomodulator approved for relapsing-remitting multiple sclerosis (MS). The objective of this post hoc analysis of the phase 3, pooled TEMSO (NCT00134563) and TOWER (NCT00751881) dataset is to evaluate the effect of teriflunomide treatment on annualised relapse rate and disability worsening across patient subgroups defined according to prior disease-modifying therapy exposure. This analysis provides further supportive evidence for a consistent effect of teriflunomide across a broad range of patients with relapsing MS, including patients who have used and discontinued other disease-modifying therapies.
authors.affiliation: University of Ottawa and The Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada.
authors.forename: Mark S
authors.initials: MS
authors.lastname: Freedman
authors.affiliation: Multiple Sclerosis Research Group and MRI-Analysis Center, McGovern Medical School, UTHealth, Houston, TX, USA.
authors.forename: Jerry S
authors.initials: JS
authors.lastname: Wolinsky
authors.affiliation: Department of Neurology, University Vita-Salute San Raffaele, Milan, Italy.
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Comi
authors.affiliation: Neurology and Department of Biomedicine, University Hospital Basel, Basel, Switzerland.
authors.forename: Ludwig
authors.initials: L
authors.lastname: Kappos
authors.affiliation: Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
authors.forename: Tomas P
authors.initials: TP
authors.lastname: Olsson
authors.affiliation: The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
authors.forename: Aaron E
authors.initials: AE
authors.lastname: Miller
authors.affiliation: Sanofi Genzyme, Cambridge, MA, USA.
authors.forename: Karthinathan
authors.initials: K
authors.lastname: Thangavelu
authors.affiliation: Sanofi Genzyme, Chilly-Mazarin, France.
authors.forename: Myriam
authors.initials: M
authors.lastname: Benamor
authors.affiliation: Sanofi Genzyme, Chilly-Mazarin, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Truffinet
authors.affiliation: University of Toronto, Toronto, ON, Canada.
authors.forename: Paul W
authors.initials: PW
authors.lastname: O'Connor
mesh_terms: D000328:Adult; D003437:Crotonates / Q000494:pharmacology*; D000078332:Data Analysis; D005260:Female; D006801:Humans; D006885:Hydroxybutyrates; D007155:Immunologic Factors / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D009570:Nitriles; D012008:Recurrence; D055502:Secondary Prevention; D014052:Toluidines / Q000494:pharmacology*; D016896:Treatment Outcome
chemical_list: D003437:Crotonates; D006885:Hydroxybutyrates; D007155:Immunologic Factors; D009570:Nitriles; D014052:Toluidines; C527525:teriflunomide
keywords: ARR and disability worsening; RRMS; TEMSO; TOWER; Teriflunomide; disease-modifying treatment